Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
1.245
-0.255 (-17.00%)
At close: Nov 15, 2024, 4:00 PM
1.450
+0.205 (16.47%)
After-hours: Nov 15, 2024, 6:40 PM EST
Cue Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cue Biopharma stock have an average target of 5.00, with a low estimate of 2.00 and a high estimate of 10. The average target predicts an increase of 301.61% from the current stock price of 1.25.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 20, 2024.
Analyst Ratings
The average analyst rating for Cue Biopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +221.29% | Aug 20, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $15 → $2 | Buy | Maintains | $15 → $2 | +60.64% | Jul 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +140.96% | Jul 26, 2024 |
| Stifel | Stifel | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +542.57% | Apr 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 | Buy | Maintains | $10 | +703.21% | Apr 9, 2024 |
Financial Forecast
Revenue This Year
11.24M
from 5.49M
Increased by 104.81%
Revenue Next Year
10.19M
from 11.24M
Decreased by -9.38%
EPS This Year
-0.81
from -1.11
EPS Next Year
-0.58
from -0.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20.8M | 24.9M | 47.3M | ||
| Avg | 11.2M | 10.2M | 20.6M | ||
| Low | 6.3M | 2.0M | 4.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 278.7% | 121.8% | 363.7% | ||
| Avg | 104.8% | -9.4% | 102.0% | ||
| Low | 13.9% | -82.6% | -51.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.81 | -0.53 | -0.44 | ||
| Avg | -0.81 | -0.58 | -0.46 | ||
| Low | -0.85 | -0.68 | -0.52 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.